Analyst
Goldman Sachs
Equibles does not estimate personal net worth.
Rajan Sharma is recorded as Analyst at Goldman Sachs. Rajan Sharma has spoken on 12 earnings calls and 3 other investor events across 7 companies, most recently for Argenx SE on October 22, 2026. Those appearances were for Argenx SE (ARGX), Genmab A/S (GMAB), Zealand Pharma A/S (ZLDPF), ZEALAND PHARMA A/S, Valneva SE (VALN) and 2 other companies. The companies whose calls Rajan Sharma spoke on are classified in the Healthcare sector.
“Maybe one for Carla and I guess Karen as well. There's obviously been a lot of discussion around OPEX.”
“I've got two, one on the CRO and one on the biotech business.”
“So, firstly, just on the petrolyntide and ecapitide combination, could you just outline your target product profile there? We've also seen some data for Lilly's aloralintide interceptide combination in the EASD abstracts.”
“So, firstly, just on the petrolyntide and ecapitide combination, could you just outline your target product profile there? We've also seen some data for Lilly's aloralintide interceptide combination in the EASD abstracts.”
“Firstly, just on Kinley and just on that first line trial again, so maybe could you just help us understand, was the data that you saw in the second line trial better than you were actually expecting internally?”
Goldman Sachs
Analyst
Source not stated
ARGX
Biotechnology · Healthcare
GMAB
Biotechnology · Healthcare
ZLDPF
Biotechnology · Healthcare
ZEALAND PHARMA A/S
Biotechnology · Healthcare
VALN
Biotechnology · Healthcare
Gubra A/S
Biotechnology · Healthcare
VALNEVA
Biotechnology · Healthcare
Gubra Q2 2026
Gubra A/S
H1 Financial Results / Interim Report First Half 2026
ZEALAND PHARMA A/S
Goldman Sachs Global Healthcare Conference 2026 (Miami)
ZEALAND PHARMA A/S
Q1 2026 Financial Results
VALNEVA
